Skip to content

Schistosoma Mansoni in Mwanza Region, Tanzania

Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02162875
Acronym
SCORE_PAR
Enrollment
37500
Registered
2014-06-13
Start date
2011-03-31
Completion date
2017-01-31
Last updated
2017-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schistosoma Mansoni

Keywords

Schistosoma mansoni, treatment, school children, adults

Brief summary

The objective of this study is to determine the strategy for mass drug administration (MDA) which provides the greatest reductions in prevalence and intensity of Schistosoma mansoni in school-aged children after 4 years of intervention.

Detailed description

Intestinal schistosomiasis is caused by the blood-dwelling flatworm Schistosoma mansoni. Despite the increasing focus on the use of praziquantel against schistosomiasis infections for the last three decades many areas in Sub-Saharan Africa still have high prevalences and intensities of schistosomiasis especially among school-age children. This is true for the area of Mwanza Region of Tanzania adjacent to Lake Victoria. The study is a six arm study and includes 150 communities (25 in each arm). From each community 100 school children (aged 9-12 years), 100 first year students (aged 7-8 years) and 50 adults (aged 20-55 years) are included, diagnosed and treated with praziquantel using strategies composing of a mixture of community wide treatment (CWT), school-based treatment (SBT) and years without treatment (-T). The 100 school children provided stool specimens on three consecutive days, while the 100 first year students and 50 adults with few exceptions only provided one specimen. The treatment strategies during the 4 years for the different arms are as follows: Arm 1: CWT, CWT, CWT, CWT; Arm 2: CWT, CWT, SBT, SBT; Arm 3: CWT, CWT -T, -T; Arm 4: SBT, SBT, SBT, SBT; Arm 5: SBT, SBT, -T, -T; Arm 6: SBT, -T, SBT, -T.

Interventions

DRUGPraziquantel

Six different treatment strategies with praziquantel

Sponsors

DBL -Institute for Health Research and Development
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
7 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

-All school children and adults who consent to participate can be included

Exclusion criteria

-Those not consenting or with any chronic disease not related to schistosomiasis will be excluded

Design outcomes

Primary

MeasureTime frameDescription
Effect of Mass drug administration on prevalence and intensity of Schistosoma mansoni among children and adultsMay -October 2016 (5 months)Prevalence and intensity of Schistosoma mansoni

Secondary

MeasureTime frameDescription
Mass drug administration coverageMay -October 2016 (5 months)Coverage of treatment

Other

MeasureTime frameDescription
Cost of different treatment armMay-October 2016 (5 months)Cost of different treatment arm

Countries

Tanzania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026